{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieacxqnxnqpywgjxdsegdnhmufgqxpdzxxqwy5xk3u3d5w6sujx6m",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mpnuf7akqvo2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiarsnjkie2c65vz3adphktnelafl47ihudnvt3x4y45zsabkdpalm"
    },
    "mimeType": "image/jpeg",
    "size": 78354
  },
  "path": "/2026/07/02/fda-ai-guidance-pharma-industry-caution-tala-fakhouri-explains/?utm_campaign=rss",
  "publishedAt": "2026-07-02T08:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Health tech",
    "Pharma",
    "Artificial intelligence",
    "biotechnology",
    "drug development",
    "FDA",
    "health tech",
    "Pharmaceuticals",
    "Policy",
    "STAT+"
  ],
  "textContent": "Companies are being too conservative in how they interpret FDA's AI guidance, but the agency can do more to help, too, Tala Fakhouri says.",
  "title": "STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong",
  "updatedAt": "2026-07-02T02:16:06.000Z"
}